UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):

September 30, 2004

 

GILEAD SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

DELAWARE

 

0-19731

 

94-3047598

(State or other jurisdiction of
incorporation or organization)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA

(Address of principal executive offices)

 

94404

(Zip Code)

 

(650) 574-3000

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFD 230.425)

 

 

 

o

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

 

o

 

Pre-commencement communications pursuant to Rule 14-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

 

o

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Section 8 – OTHER EVENTS

 

Item 8.01                                             Other Events

 

On September 30, 2004, Gilead Sciences, Inc., a Delaware corporation, issued a joint press release with Genelabs Technologies, Inc. announcing that the companies have entered into a research collaboration and license agreement for the development of Genelabs’ novel Hepatitis C compounds.  A copy of the press release is filed as Exhibit 99.1 to this report.

 

Section 9 – Financial Statements and Exhibits

 

Item 9.01               Financial Statements and Exhibits

 

(c)           Exhibits

 

Exhibit
Number

 

Description

99.1

 

Press Release, issued by Gilead Sciences, Inc. on September 30, 2004

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

GILEAD SCIENCES, INC.

 

(Registrant)

 

 

 

/s/  John C. Martin

 

John C. Martin
President and
Chief Executive Officer

 

 

Date:       October 4, 2004

 

 

3


 

Exhibit Index

 

Exhibit
Number

 

Description

99.1

 

Press Release, issued by Gilead Sciences, Inc. on September 30, 2004

 

4